AstraZeneca Pharma India Limited , a leading science-led biopharmaceutical company, has announced impressive financial results for the second quarter of fiscal year 2025-26. The company demonstrated strong performance across its key business segments, reflecting its commitment to innovation and market leadership.

Financial Highlights

AstraZeneca Pharma India reported significant growth in its Q2 FY2025-26 results:

The company's revenue saw a substantial increase of 37% year-over-year, rising from ₹4,080.00 crore in Q2 FY2024-25 to ₹5,590.90 crore in Q2 FY2025-26. This growth was primarily driven by strong performance across the company's therapy areas, particularly in Oncology and Biopharmaceuticals.

Segment-wise Performance

AstraZeneca's growth was broad-based across its key therapeutic areas:

The Oncology segment continued to be the primary growth driver, while the Rare Disease segment, though smaller in absolute terms, showed remarkable growth.

Key Developments

During the first half of FY2025-26, AstraZeneca Pharma India achieved several significant milestones:

1. Received seven new regulatory approvals, reinforcing its leadership across therapy areas.
2. Launched Eculizumab, the first anti-complement therapy approved in India for treating atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
3. Gained additional indications for key drugs including Durvalumab, Osimertinib, and Trastuzumab deruxtecan, expanding their use in various cancer treatments.

Management Commentary

Bhavana Agrawal, Chief Financial Officer & Director, stated, "Our strong Q2/H1 results reflect AstraZeneca's strong growth trajectory and unwavering commitment to science-led progress. We continue to strengthen our leadership across therapy areas by advancing an innovation-first portfolio that delivers both patient impact and business value."

Praveen Akkinepally, Country President & Managing Director, added, "Our performance this quarter is a clear testament to AstraZeneca's purpose in action, translating cutting-edge science into life-changing medicines for patients in India. As we scale across our therapy areas, our focus on innovation, partnerships, and patient-centricity is shaping a more accessible and outcomes-driven healthcare ecosystem."

Outlook

With its strong performance in Q2 and the first half of FY2025-26, AstraZeneca Pharma India Limited appears well-positioned to maintain its growth momentum. The company's focus on innovation, expanding its product portfolio, and gaining additional indications for existing drugs is likely to drive future growth and reinforce its market leadership in key therapeutic areas.

Investors and stakeholders can expect AstraZeneca to continue its emphasis on research and development, strategic partnerships, and market expansion to sustain its growth trajectory in the coming quarters.

AstraZeneca Pharma India Limited is set to introduce a new treatment for hyperkalaemia in adult patients. The company has announced the launch of Sodium Zirconium Cyclosilicate powder, marketed under the brand name Lokelma, for oral suspension in November 2025.

Regulatory Approval and Product Details

AstraZeneca Pharma India received Import and Marketing Permission from the Drugs Controller General of India (DCGI) in March 2025 for both 5g and 10g formulations of Lokelma. However, the company has decided to initially launch only the 5g version of the product.

Key Information

Significance of the Launch

The introduction of Lokelma represents a new treatment option for adult patients suffering from hyperkalaemia, a condition characterized by elevated potassium levels in the blood. This launch aligns with AstraZeneca's commitment to addressing unmet medical needs and expanding its portfolio in the Indian pharmaceutical market.

Company Communication

AstraZeneca Pharma India Limited has officially communicated this development to both the BSE Limited and the National Stock Exchange of India Limited on October 15, 2025. This transparency in communication demonstrates the company's adherence to regulatory requirements and its commitment to keeping stakeholders informed about significant product launches.

The launch of Lokelma could potentially impact AstraZeneca Pharma India's market position in the treatment of hyperkalaemia and may be of interest to investors and healthcare professionals alike.